Capital Research Global Investors
IMGN

Capital Research Global Investors’s Immunogen Inc IMGN Stock Holding History

Capital Research Global Investors’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7,095,570
Closed -$67.2M – 447
2018
Q3 		$67.2M Sell
7,095,570
-2,335,430
-25% -$22.5M 0.02% 314
2018
Q2 		$91.8M Buy
9,431,000
+3,923,000
+71% +$41.4M 0.03% 296
2018
Q1 		$57.9M Buy
+5,508,000
New +$54.4M 0.02% 332

Other funds holding IMGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors's IMGN Position: Q4 2018 in Review

Capital Research Global Investors sold out of Immunogen Inc (IMGN) in Q4 2018, closing a stake of 7,095,570 shares — an estimated $67.2M sold.

Capital Research Global Investors first reported a position in IMGN in Q1 2018 and held it in 3 quarters. The position peaked at $91.8M in Q2 2018. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2018.

  • Capital Research Global Investors reported no remaining Immunogen Inc position as of Q4 2018 after selling out during the quarter.
  • Capital Research Global Investors sold 7,095,570 Immunogen Inc shares in Q4 2018, an estimated $67.2M.
  • Capital Research Global Investors first reported a position in Immunogen Inc in Q1 2018 and held it in 3 quarters.
  • Capital Research Global Investors's Immunogen Inc position peaked at $91.8M in Q2 2018.
  • 200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2018.

Based on Capital Research Global Investors's 13F filing for Q4 2018, filed 14 Feb 2019.